This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paroxysmal Tachycardia발작성 빈맥

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I47 (Paroxysmal tachycardia) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsParoxysmal supraventricular tachycardia (PSVT), atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia (AVRT), ventricular tachycardia (VT), Torsades de Pointes, WPW syndrome-associated tachycardia, inappropriate sinus tachycardia (IST)
C. Adult onsetAVNRT occurs predominantly in women in their 30s–40s, and ventricular tachycardia occurs mainly in men in their 50s–70s and in patients with underlying heart disease. AVRT (WPW) is congenital and can present at any age.
1. HistoryBouveret's description of paroxysmal tachycardia cases in 1889, the discovery of WPW syndrome in 1930, and the introduction of radiofrequency catheter ablation in 1982 changed the treatment paradigm.
2. CausesCauses include congenital conduction abnormalities (accessory pathways, dual AV nodal conduction), autonomic imbalance, ischemic heart disease, cardiomyopathy, electrolyte abnormalities, and drugs.
3. GeneticsVariants in the KCNQ1, KCNH2, SCN5A, PRKAG2, and HCN4 genes are associated with a predisposition to congenital paroxysmal tachycardia.
4. General epidemiologySupraventricular tachycardia (SVT) occurs in about 2.25/1000 of the general population, with a lifetime prevalence of about 0.2–0.4%. Ventricular tachycardia occurs at a much higher frequency in patients with underlying heart disease.
5. PathophysiologyIt arises from three electrophysiologic mechanisms: reentry, increased automaticity, and triggered activity.
6. SymptomsPalpitations that start and stop abruptly, dizziness, presyncope, dyspnea, chest pain. Ventricular tachycardia may be accompanied by hemodynamic instability.
7. SignsRapid, regular pulse (150–250/min), frog sign of the neck veins, blood pressure fluctuation, characteristic tachycardia pattern observed on the electrocardiogram.
8. Screening12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders are the primary screening tests. EPS is needed in high-risk groups (syncope, WPW).
9. DiagnosisRecording a 12-lead ECG during a tachycardia episode is key. Vagal maneuvers and EPS to define the mechanism. Echocardiography to evaluate structural abnormalities.
10. TreatmentAcute phase: vagal maneuvers, intravenous adenosine, synchronized cardioversion. Long term: catheter ablation (SVT/accessory pathway, curative), antiarrhythmic drugs, ICD (ventricular tachycardia).
11. PrognosisAVNRT/AVRT are cured in over 95% by catheter ablation. Ventricular tachycardia varies with the underlying heart disease, and ongoing management of the risk of recurrence and sudden death is needed.
12. PreventionAvoidance of triggers (caffeine, alcohol, stress), treatment of underlying heart disease, and prophylactic ablation of high-risk WPW accessory pathways are recommended.
13. ReferencesCommon Types of Supraventricular Tachycardia: Diagnosis and Management (AFP, 2023) … and 9 other papers

1. History

The clinical description of paroxysmal tachycardia dates back to the late 19th century. In 1889, the French internist Léon Bouveret described in detail a syndrome of rapid heartbeat that begins and ends with sudden attacks, which was named after him "Bouveret's disease (Maladie de Bouveret)". This is an early description corresponding to present-day paroxysmal supraventricular tachycardia (PSVT). In 1903, Wilhelm His Jr. described the electrical conduction pathway between the atria and ventricles through studies of the atrioventricular node, which later became the foundation for understanding the pathophysiology of paroxysmal tachycardia.

In 1930, Louis Wolff, John Parkinson, and Paul White reported a syndrome characterized by a short PR interval, a preexcitation wave (delta wave), and paroxysmal tachycardia, and WPW syndrome was named. This discovery was the first clinical indication of the existence of an atrioventricular accessory pathway and subsequently became a catalyst for electrophysiologic research. As intracardiac electrophysiologic studies by Durrer, Wellens, and others advanced in the 1960s, the mechanisms of AVNRT (atrioventricular nodal reentrant tachycardia) and AVRT (atrioventricular reentrant tachycardia) were elucidated in detail.

A revolution in treatment came with the introduction of catheter ablation in the 1980s. In 1982, Gallagher et al. successfully performed accessory pathway ablation using direct current (DC) energy, and in 1987 Jackman and Kuck developed catheter ablation using radiofrequency (RF) energy. RF ablation replaced the earlier surgical interruption of accessory pathways and became established as a rapid, effective, and minimally invasive curative method. Subsequently, the introduction of three-dimensional electroanatomic mapping systems made it possible to precisely visualize and ablate complex arrhythmia substrates. Recently, advances in cryoablation, contact force-sensing catheters, and fluoroless ablation techniques have further improved procedural safety and success rates.


2. Causes

The causes of paroxysmal tachycardia differ by type. AVNRT, the most common type of paroxysmal supraventricular tachycardia (PSVT), is based on dual AV nodal pathways, in which two conduction pathways with different conduction velocities and refractory periods (a fast pathway and a slow pathway) coexist within the atrioventricular node. The congenital presence of these dual pathways is the structural basis of AVNRT, and a single premature atrial contraction acts as the trigger to form a reentry circuit.

AVRT is caused by the congenital presence of an accessory pathway (Kent bundle) outside the atrioventricular node, forming an additional electrical connection between the atria and ventricles. WPW syndrome is the case in which conduction of electrical impulses through this accessory pathway can be identified on the electrocardiogram; in some, as a concealed pathway, only retrograde conduction is possible, and preexcitation findings do not appear on the ECG. Inappropriate sinus tachycardia (IST) is caused by sympathetic overactivity or autonomic abnormality of the sinoatrial node and is often associated with POTS (postural orthostatic tachycardia syndrome).

The main causes of ventricular tachycardia (VT) are myocardial scarring due to coronary artery disease (scar-related VT), nonischemic cardiomyopathy, ARVC, hypertrophic cardiomyopathy, etc. Slow conduction channels formed at the border of scar tissue form an important substrate for reentry circuits. Electrolyte abnormalities (hypokalemia, hypomagnesemia), drug toxicity (QT-prolonging drugs), and metabolic abnormalities can also trigger ventricular tachycardia.


3. Genetics

The genetic basis of paroxysmal tachycardia varies by type. Specific gene variants associated with AVNRT have not yet been clearly identified, but familial cases suggesting a genetic predisposition to dual AV nodal conduction properties have been reported.

In the sporadic form of WPW syndrome, specific gene variants are often not identified, but familial WPW is associated with variants in the PRKAG2 (AMP-activated protein kinase γ2 subunit) gene. PRKAG2 variants cause cardiac glycogen storage disease, characterized by preexcitation, atrial fibrillation, and myocardial hypertrophy. Inherited diseases associated with paroxysmal ventricular tachycardia include CPVT (RYR2, CASQ2 genes), long QT syndrome (KCNQ1, KCNH2, SCN5A, etc.), short QT syndrome (KCNQ1, KCNH2 gain-of-function), and Brugada syndrome (SCN5A).

The HCN4 gene encodes the channel that regulates the 'funny' current (If) of the sinoatrial node, and variants in this gene are associated with sinus tachycardia and inappropriate sinus tachycardia. When an inherited tachycardia syndrome is suspected, next-generation sequencing (NGS)-based cardiac channelopathy panel testing is recommended. If genetic testing is positive, clinical evaluation of first-degree relatives (ECG, exercise stress testing, Holter monitoring) is needed.


4. General epidemiology

Paroxysmal supraventricular tachycardia (PSVT) is a common arrhythmia in the general population, with an estimated incidence of about 35 per 100,000 per year and a prevalence of about 225 per 100,000 (Orejarena et al., 1998). About 10–15% of all cardiology outpatients are known to present with paroxysmal tachycardia as the chief complaint. Women have about twice the prevalence of men, and AVNRT occurs most commonly in women in their 30s–40s.

AVNRT accounts for about 60% of PSVT, AVRT for about 30%, and inappropriate sinus tachycardia and others for about 10%. WPW syndrome is found in 0.1–0.3% of the general population. In high-risk WPW patients, the risk of sudden cardiac death is reported at about 0.15–0.4% per year.

Ventricular tachycardia (VT) can occur idiopathically even without structural heart disease (idiopathic ventricular tachycardia, about 10% of all VT). VT with structural heart disease has a poor prognosis and occurs most commonly in patients with ischemic cardiomyopathy. Nonsustained VT (NSVT) is observed at a frequency of about 2–3% in the general population but has important clinical significance when underlying heart disease is present. The age-related increase in prevalence is prominent in VT, and hospitalizations related to ventricular tachycardia rise sharply after age 60.


5. Pathophysiology

The electrophysiologic mechanisms of paroxysmal tachycardia are broadly classified into three: reentry, enhanced automaticity, and triggered activity.

Reentry is the most common mechanism; it requires two pathways with different conduction velocities and refractory periods that are anatomically or functionally separated, a unidirectional block, and sufficiently slow conduction. When a premature atrial contraction acts as a trigger while the fast pathway is refractory and conduction occurs through the slow pathway, and the fast pathway then recovers and conducts retrogradely, a reentry circuit is formed. AVNRT, AVRT, and scar-related VT all arise from this mechanism.

Enhanced automaticity is a phenomenon in which spontaneous depolarization accelerates in tissue other than the sinoatrial node, driving the heartbeat at a faster rate than the sinoatrial node. Ectopic atrial tachycardia, accelerated junctional rhythm, and some idiopathic ventricular tachycardias arise from this mechanism. Catecholamine excess, ischemia, and digitalis toxicity increase automaticity.

Triggered activity arises from afterdepolarizations caused by a preceding action potential. Early afterdepolarizations (EAD) occur in QT-prolonged states and cause Torsades de Pointes, and delayed afterdepolarizations (DAD) occur in states of intracellular calcium overload and are the mechanism of CPVT and digitalis-toxic VT. At the cellular level, spontaneous calcium release due to RYR2 dysfunction causes DADs.


6. Symptoms

The most characteristic symptom of paroxysmal tachycardia is palpitation that begins with a sudden attack and ends abruptly. Patients usually describe it as "my heart suddenly started beating fast and then suddenly stopped," which is an important clue for differentiation from other arrhythmias. While the tachycardia persists, a regular, rapid heartbeat is felt, and the pulsation may be felt in the neck or chest.

Dizziness and presyncope reflect reduced cardiac output due to the rapid heart rate. Actual syncope occurs particularly with hemodynamically unstable tachycardia, tachycardia occurring in the upright position, or accompanying atrioventricular block. Dyspnea and chest pain are more severe especially in patients with underlying heart disease, and when ventricular tachycardia is accompanied by hemodynamic instability, symptoms of shock (hypotension, cyanosis, decreased consciousness) may appear. In AVNRT, neck pulsations, in which regular pulsations are felt in the neck, are characteristically reported; they occur because the atria and ventricles contract almost simultaneously, causing atrial regurgitation against the tricuspid valve.

Polyuria may appear after a tachycardia episode and is attributed to increased secretion of atrial natriuretic peptide (ANP) due to atrial distension.


7. Signs

The most important sign observed during an episode of paroxysmal tachycardia is a rapid, regular pulse. The heart rate is usually in the range of 150–250/min and is almost always regular in AVNRT and AVRT. The pulse is so fast that it is difficult for patients to measure it themselves at the wrist. In AVNRT, the frog sign of the jugular veins — a phenomenon in which the neck veins pulsate rapidly with each heartbeat — is characteristically observed. This is the visible appearance in the neck of the regurgitant wave produced as the atria contract against a closed tricuspid valve.

Blood pressure may be normal or mildly decreased during tachycardia, and in ventricular tachycardia marked hypotension (systolic below 90mmHg) may occur. On cardiac auscultation during a tachycardia episode, regular, rapid heart sounds are heard, and in ventricular tachycardia the intensity of the heart sounds may vary irregularly along with cannon A waves due to atrioventricular dissociation. Sweating and facial flushing may accompany it due to sympathetic activation.


8. Screening

Screening for paroxysmal tachycardia proceeds in stages according to the symptom pattern and risk. A 12-lead electrocardiogram (ECG) is performed as a baseline in all patients, and when a recording is obtained during a tachycardia episode, the type of tachycardia can be classified by the QRS morphology, the position and direction of the P wave, the tachycardia cycle, etc. During sinus rhythm, a WPW pattern (short PR, delta wave) can be identified, in which case additional tests to evaluate a high-risk accessory pathway are needed.

24–48-hour Holter monitoring is useful for capturing tachycardia episodes in patients whose symptoms occur daily or every few days. When symptoms occur infrequently, an event recorder or a smartphone-linked ECG device can be used to record the ECG immediately when symptoms occur. For tachycardia that occurs very rarely, an implantable loop recorder (ILR) is most effective for long-term monitoring.

Exercise stress testing is performed when CPVT is suspected (palpitations during exercise, exercise-associated syncope) and to evaluate for concomitant ischemic heart disease. An electrophysiologic study (EPS) is performed to induce the tachycardia and evaluate its mechanism in patients scheduled for catheter ablation, high-risk WPW syndrome groups, and patients with unexplained syncope.


9. Diagnosis

A 12-lead ECG recorded during a tachycardia episode is essential for an accurate diagnosis of the type of paroxysmal tachycardia. The key elements of ECG analysis are the QRS morphology (narrow vs. wide), the position (before, after, or within the QRS) and axis of the P wave, the RP interval (short RP vs. long RP), and the regularity of the tachycardia.

Narrow QRS tachycardia (QRS <120ms) is mostly of supraventricular origin and is differentiated into AVNRT, AVRT, sinus tachycardia, ectopic atrial tachycardia, atrial flutter, etc. Typical findings of AVNRT are a P wave buried within the QRS or located just after the QRS (short RP), and a pseudo-R' pattern in V1. Wide QRS tachycardia (QRS ≥120ms) may be ventricular tachycardia, supraventricular tachycardia with intraventricular conduction abnormality, or antidromic AVRT in WPW, and the Brugada criteria, Vereckei criteria, etc. are applied for differentiation. Wide QRS tachycardia accompanied by hemodynamic instability is regarded as ventricular tachycardia and treated immediately.

Vagal maneuvers (carotid sinus massage, Valsalva maneuver) temporarily terminate AVNRT and AVRT or provide diagnostic information during tachycardia. Rapid intravenous administration of adenosine 6–12mg is a diagnostic/therapeutic maneuver that temporarily terminates AV node-dependent tachycardia. With an electrophysiologic study, the tachycardia is induced, and its mechanism is finally confirmed through His-Purkinje conduction system recording and pacing techniques.


10. Treatment

Treatment of paroxysmal tachycardia is divided into acute termination of tachycardia and long-term prevention of recurrence.

In acute-phase treatment of hemodynamically stable supraventricular tachycardia (narrow QRS), vagal maneuvers — the modified Valsalva maneuver, ice-water facial immersion, carotid sinus massage (unilateral, in older adults/without vascular stenosis) — are performed first. If vagal maneuvers fail, adenosine (6–12mg rapid intravenous administration) is the first-line drug in AVNRT and AVRT. If there is no response to adenosine or adenosine is contraindicated, intravenous diltiazem, verapamil (calcium channel blockers), or beta-blockers are given. In hemodynamically unstable tachycardia (altered consciousness, blood pressure <90mmHg, chest pain, pulmonary edema), immediate synchronized cardioversion is essential.

In long-term treatment of symptomatic AVNRT, AVRT, or WPW-related tachycardia, catheter ablation is the Class I recommended treatment. The success rate of catheter ablation using RF or cryo energy is 97–99% for AVNRT and 93–95% for AVRT, with a recurrence rate below 3–5%. When ablation is not desired or not indicated, beta-blockers, nondihydropyridine calcium channel blockers, or flecainide (in the absence of structural heart disease) are used. In ventricular tachycardia, correction of underlying heart disease, antiarrhythmic drugs (amiodarone, sotalol), ICD implantation, and catheter ablation of the ventricular tachycardia substrate are individualized.


11. Prognosis

The prognosis of paroxysmal tachycardia differs greatly by type. AVNRT is a benign arrhythmia that is not life-threatening in the absence of structural heart disease and has a cure rate of over 97% with catheter ablation. The recurrence rate after ablation is about 2–3%. In terms of quality of life, repeated tachycardia episodes can cause considerable anxiety, social limitations, and reduced work capacity, justifying active treatment.

In WPW syndrome, the risk of sudden cardiac death is generally low (0.15–0.4% per year), but when high-risk features are present (shortest preexcited RR/accessory pathway refractory period ≤250ms, concomitant atrial fibrillation, history of syncope during tachycardia), prophylactic catheter ablation is recommended. The recurrence rate after ablation is less than 5%.

The prognosis of ventricular tachycardia depends absolutely on the underlying heart disease. Idiopathic ventricular tachycardia without structural heart disease (right ventricular outflow tract origin, left ventricular papillary muscle origin, etc.) generally has a benign prognosis and can be cured with catheter ablation. In contrast, scar-related VT due to ischemic cardiomyopathy has a high recurrence rate and a risk of sudden cardiac death, so ICD implantation is essential. If recurrent VT persists even after the ICD delivers appropriate shocks, the goal is to reduce the VT burden with amiodarone or VT catheter ablation.


12. Prevention

Prevention of recurrence of paroxysmal tachycardia consists of trigger management, drug therapy, and procedural treatment. As lifestyle modification, it is important to identify and avoid tachycardia triggers such as excessive caffeine intake, alcohol, sleep deprivation, and extreme stress. In some patients, smoking and certain drugs (stimulants, sympathomimetics) are also triggers.

In confirmed AVNRT or AVRT, catheter ablation is the most effective means of prevention. In patients who do not choose the procedure, beta-blockers or nondihydropyridine calcium channel blockers (diltiazem, verapamil) are used to prevent recurrence. It is also useful to teach patients vagal maneuver techniques so that they can terminate tachycardia episodes themselves at home.

In high-risk WPW patients, regardless of symptoms, the electrophysiologic properties of the accessory pathway are evaluated, and if judged high-risk, prophylactic catheter ablation is recommended (especially in high-risk occupations such as airline pilots and drivers). To prevent recurrence of ventricular tachycardia, optimal treatment of the underlying heart disease (ischemic heart disease, heart failure, cardiomyopathy) is the fundamental preventive measure.


13. References

  1. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. J Am Coll Cardiol. 2016;67(13):e27-e115. DOI: 10.1016/j.jacc.2015.08.856. PMID: 26409235.

  2. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020;41(5):655-720. DOI: 10.1093/eurheartj/ehz467. PMID: 31504425.

  3. Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53(19):1791-1797. DOI: 10.1016/j.jacc.2009.02.014. PMID: 19422992.

  4. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867. DOI: 10.1093/eurheartj/ehv316. PMID: 26320108.

  5. Katritsis DG, Josephson ME. Differential diagnosis of regular, narrow-QRS tachycardias. Heart Rhythm. 2015;12(7):1667-1676. DOI: 10.1016/j.hrthm.2015.03.046. PMID: 25820131.

  6. Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med. 1991;324(23):1605-1611. DOI: 10.1056/NEJM199106063242301. PMID: 2030721.

  7. Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374(23):2235-2245. DOI: 10.1056/NEJMoa1602014. PMID: 27042964.

  8. Fetics BJ, Nevo E, Chen CH, Kass DA. Parametric model derivation of transfer function for noninvasive estimation of aortic pressure by radial tonometry. IEEE Trans Biomed Eng. 1999;46(6):698-706. DOI: 10.1109/10.764946. PMID: 10356876.

  9. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150-157. DOI: 10.1016/s0735-1097(97)00422-1. PMID: 9426034.

  10. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest. 1989;95(2 Suppl):118S-127S. DOI: 10.1378/chest.95.2_Supplement.118S. PMID: 2463469.